LECT2通过调控炎症性单核细胞限制肝细胞癌的生长与进展
该研究利用肝细胞癌小鼠模型和人肝细胞癌样本,揭示LECT2既影响肿瘤表型又重塑免疫微环境;LECT2缺失使Ctnnb-1突变肿瘤肝细胞上皮间质转化能力增强,并促进具有免疫抑制和促瘤潜能的炎症性单核细胞积聚;人肝细胞癌中LECT2低水平与高肿瘤分级和炎症浸润相关。
要点
- LECT2缺失增强Ctnnb-1突变肿瘤肝细胞的上皮间质转化能力。
- LECT2缺失促进具有免疫抑制特性的炎症性单核细胞积聚。
- 人肝细胞癌中LECT2低水平与高肿瘤分级和炎症浸润相关。
核心结论
- LECT2是肝脏肿瘤发生的关键调控因子,其缺失重塑肿瘤微环境和肿瘤表型,提示LECT2是有前景的肝细胞癌免疫治疗选择。
研究设计与样本
- 研究使用肝细胞癌小鼠模型和人肝细胞癌样本。
主要发现
- LECT2缺失使Ctnnb-1突变肿瘤肝细胞上皮间质转化能力增强。
- LECT2缺失促进具有免疫抑制特性和强促瘤潜能的炎症性单核细胞积聚。
- 人肝细胞癌中LECT2低水平与高肿瘤分级和炎症浸润存在强关联。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Leukocyte cell-derived chemotaxin-2 (LECT2) was originally identified as a hepatocyte-secreted chemokine-like factor and a positive target of β-catenin signaling. Here, we dissected out the mechanisms by which LECT2 modulates hepatocellular carcinoma (HCC) development using both HCC mouse models and human HCC samples. We have demonstrated that LECT2 exhibits dual abilities as it has profound repercussions on the tumor phenotype itself and the immune microenvironment. Its absence confers Ctnnb-1-mutated tumor hepatocytes a stronger ability to undergo epithelial to mesenchymal transition and fosters the accumulation of pejorative inflammatory monocytes harboring immunosuppressive properties and strong tumor-promoting potential. Consistent with our HCC mouse model, a low level of LECT2 in human HCC is strongly associated with high tumor grade and the presence of inflammatory infiltrates, emphasizing the clinical value of LECT2 in human liver tumorigenesis. Conclusion: Our findings have demonstrated that LECT2 is a key player in liver tumorigenesis because its absence reshapes the tumor microenvironment and the tumor phenotype, revealing LECT2 as a promising immunotherapeutic option for HCC.
引用
- L'Hermitte A, Pham S, Cadoux M, et al. Lect2 Controls Inflammatory Monocytes to Constrain the Growth and Progression of Hepatocellular Carcinoma. Hepatology. 2018. PMID: 30070727. doi:10.1002/hep.30140
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。